Roquefort Therapeutics Company Description

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer.

Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action.

The company was incorporated in 2020 and is based in London, the United Kingdom.

Roquefort Therapeutics plc

Country	United Kingdom
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Darrin Disley

Contact Details

Address: 85 Great Portland Street London, W1W 7LT United Kingdom
Phone	44 20 3918 8633
Website	roquefortplc.com

Stock Details

Ticker Symbol	ROQ
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BMDQ2T15
SIC Code	6726

Key Executives

Name	Position
Stephen Paul West B.Com, CA	Executive Chairman